PT3283058T - Comprimido de ribociclib - Google Patents

Comprimido de ribociclib

Info

Publication number
PT3283058T
PT3283058T PT167180207T PT16718020T PT3283058T PT 3283058 T PT3283058 T PT 3283058T PT 167180207 T PT167180207 T PT 167180207T PT 16718020 T PT16718020 T PT 16718020T PT 3283058 T PT3283058 T PT 3283058T
Authority
PT
Portugal
Prior art keywords
ribociclib
tablet
ribociclib tablet
Prior art date
Application number
PT167180207T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3283058(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3283058T publication Critical patent/PT3283058T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT167180207T 2015-04-16 2016-04-14 Comprimido de ribociclib PT3283058T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
PT3283058T true PT3283058T (pt) 2023-02-03

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167180207T PT3283058T (pt) 2015-04-16 2016-04-14 Comprimido de ribociclib

Country Status (29)

Country Link
US (6) US10799506B2 (OSRAM)
EP (3) EP4197530B1 (OSRAM)
JP (1) JP2018514523A (OSRAM)
KR (2) KR102750931B1 (OSRAM)
CN (2) CN107530292B (OSRAM)
AR (1) AR104257A1 (OSRAM)
AU (5) AU2016248017A1 (OSRAM)
BR (1) BR112017021283A2 (OSRAM)
CA (1) CA2982425C (OSRAM)
CL (1) CL2017002593A1 (OSRAM)
CO (1) CO2017010510A2 (OSRAM)
DK (1) DK3283058T3 (OSRAM)
EA (1) EA201792290A1 (OSRAM)
EC (1) ECSP17075052A (OSRAM)
ES (1) ES2938261T3 (OSRAM)
FI (1) FI3283058T3 (OSRAM)
HR (1) HRP20230053T1 (OSRAM)
HU (1) HUE061213T2 (OSRAM)
IL (1) IL254818A0 (OSRAM)
MX (1) MX2017013350A (OSRAM)
PE (1) PE20180035A1 (OSRAM)
PH (1) PH12017501820A1 (OSRAM)
PL (1) PL3283058T3 (OSRAM)
PT (1) PT3283058T (OSRAM)
SG (1) SG11201708084PA (OSRAM)
SI (1) SI3283058T1 (OSRAM)
TN (1) TN2017000422A1 (OSRAM)
TW (1) TW201642864A (OSRAM)
WO (1) WO2016166703A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
JP7681599B2 (ja) 2019-12-16 2025-05-22 ルネラ・バイオテック・インコーポレーテッド 選択的cdk4/6阻害剤のがん治療薬
KR20220113986A (ko) 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
US20230355578A1 (en) * 2020-09-29 2023-11-09 Laboratorios Silanes S.A. De C.V. Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳-法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
JP3672314B2 (ja) * 1994-07-12 2005-07-20 バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド 防湿性フィルム被覆材組成物、方法および被覆成形物
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
US20110070301A1 (en) * 2009-09-24 2011-03-24 Luber Joseph R Orally transformable tablets
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
SG192666A1 (en) * 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
JP6226978B2 (ja) * 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター(sarm)によりアンドロゲン受容体(ar)陽性乳癌を処置する方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
SI3283058T1 (sl) 2023-03-31
US20250090531A1 (en) 2025-03-20
CN115554257A (zh) 2023-01-03
KR20170137101A (ko) 2017-12-12
CA2982425A1 (en) 2016-10-20
MX2017013350A (es) 2018-01-25
US20250127785A1 (en) 2025-04-24
US20250134893A1 (en) 2025-05-01
CL2017002593A1 (es) 2018-05-18
AU2019201929B2 (en) 2020-07-09
PL3283058T3 (pl) 2023-03-20
JP2018514523A (ja) 2018-06-07
TN2017000422A1 (en) 2019-01-16
EP4197530B1 (en) 2025-11-12
EP4197530A1 (en) 2023-06-21
US20230104792A1 (en) 2023-04-06
EP3283058A1 (en) 2018-02-21
AU2022215155A1 (en) 2022-09-01
EP4620458A3 (en) 2025-10-22
CO2017010510A2 (es) 2018-03-20
ES2938261T3 (es) 2023-04-05
AU2016248017A1 (en) 2017-10-19
BR112017021283A2 (pt) 2018-06-26
PE20180035A1 (es) 2018-01-09
CN107530292B (zh) 2022-11-01
PH12017501820A1 (en) 2018-04-23
EP3283058B1 (en) 2022-11-16
HUE061213T2 (hu) 2023-05-28
US20200390771A1 (en) 2020-12-17
DK3283058T3 (da) 2023-02-13
US10799506B2 (en) 2020-10-13
KR102750931B1 (ko) 2025-01-09
KR20250009572A (ko) 2025-01-17
AU2022215155B2 (en) 2024-08-01
ECSP17075052A (es) 2018-02-28
CA2982425C (en) 2023-10-31
FI3283058T3 (fi) 2023-03-01
AU2019201929A1 (en) 2019-04-11
CN107530292A (zh) 2018-01-02
AU2020250190A1 (en) 2020-11-05
EP4620458A2 (en) 2025-09-24
HRP20230053T1 (hr) 2023-03-03
WO2016166703A1 (en) 2016-10-20
AR104257A1 (es) 2017-07-05
TW201642864A (zh) 2016-12-16
SG11201708084PA (en) 2017-10-30
AU2024227794A1 (en) 2024-11-21
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
EA201792290A1 (ru) 2018-02-28
IL254818A0 (en) 2017-12-31
US12064434B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
GB201707959D0 (en) No details
AU356804S (en) Tablet
DK3250592T3 (en) Anti-transthyretin-antistoffer
IL254818A0 (en) Ribociclib tablet
GB201706130D0 (en) No details
DK3284069T3 (en) Pos-terminal
SG11201800591TA (en) Tablet
GB201615071D0 (en) No details
GB201612542D0 (en) no details
DK3272750T3 (en) Morphinan-derivat
GB201709180D0 (en) No details
GB201420300D0 (en) Tablet
AU361999S (en) Ballustrade
GB201616225D0 (en) No details
DK3133099T3 (en) Polymermodificeret polyoldispersion
AU356801S (en) Tablet
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201708207D0 (en) No details
DK3282866T3 (en) Proteinfibre
GB201511252D0 (en) Tablet
DK3250312T3 (en) Urea-metalnitrat-scr-system
DK3294653T3 (en) Justerbar inline-port
GB201702336D0 (en) No details